Abel Cordoba, El Hajj Houssein, Alexandre Escande, Cyrielle Scouarnec, Fabrice Narducci, Carlos Martinez Gomez, Eric Leblanc, Delphine Hudry, Camille Pasquesoone, Sophie Taieb, Xavier Mirabel, Eric F Lartigau, Florence Le Tinier
OBJECTIVE: Brachytherapy of the vaginal dome is the recommended adjuvant treatment for intermediate-risk endometrial cancer. This study assessed the results of dosimetric planning of high-dose-rate brachytherapy exclusively in the first treatment session. STUDY DESIGN: This retrospective study included all patients who underwent hysterectomy for endometrial cancer followed by adjuvant brachytherapy of the vaginal dome between 2012 and 2015. Local recurrence rates, overall survival (OS) rates, recurrence-free survival (RFS) rates, and related acute and late toxicity rates were evaluated...
April 30, 2024: European Journal of Obstetrics, Gynecology, and Reproductive Biology